A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults

Key Inclusion Criteria:

• Has a SARS-CoV-2 negative test result from a sample collected ≤72 hours prior to randomization as described in the protocol
• Has received complete primary series of standard-of-care COVID-19 vaccination per local guidance, completed at least 2 weeks prior to screening
• Has a body mass index (BMI) between 18 and 31 Kg/m^2 (inclusive) at the screening visit
• Is judged by the investigator to be in good health based on medical history, physical examination, vital sign measurements, and electrocardiogram (ECG)s performed at screening and/or prior to administration of initial dose of study drug

Key Exclusion Criteria:

• History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, infectious, autoimmune, oncologic, psychiatric or neurological disease, as assessed by the investigator as described in the protocol
• Presents any concern to the investigator that might confound the results of the study or poses an additional risk to the participant by their participation in the study
• Was hospitalized (ie, >24 hours) for any reason within 30 days of the screening visit
• Has history of alcohol or drug abuse as determined by the investigator
• Has a history of significant multiple and/or severe allergies (eg, latex gloves), or has had an anaphylactic reaction to prescription or non-prescription drugs or food

NOTE: Other protocol defined inclusion / exclusion criteria apply